Related Experiment Videos
Bacillus Calmette-Guérin immunotherapy. Techniques and results
1Division of Urology, UCLA Medical Center.
The Urologic Clinics of North America
|August 1, 1992
Summary
Intravesical bacillus Calmette-Guérin (BCG) therapy is crucial for treating bladder cancer stages Ta, T1, and carcinoma in situ (CIS). Proper patient selection and protocol adherence maximize BCG
Area of Science:
- Urology
- Oncology
- Immunotherapy
Background:
- Intravesical bacillus Calmette-Guérin (BCG) is a key treatment for non-muscle invasive bladder cancer.
- Effective management of transitional-cell carcinoma (TCC) and carcinoma in situ (CIS) is critical.
Purpose of the Study:
- To highlight the importance of appropriate patient selection for intravesical BCG therapy.
- To emphasize the efficacy of BCG in preventing tumor recurrence and eradicating residual disease.
Main Methods:
- Review of intravesical BCG protocols for bladder cancer management.
- Analysis of patient selection criteria for optimal treatment outcomes.
Main Results:
- BCG prevents tumor recurrence in up to 80% of appropriately selected patients.
- Residual tumor is eradicated in 60% and CIS eliminated in 70% of patients.
- Proper protocol assignment is essential for BCG effectiveness.
Conclusions:
- Intravesical BCG is a highly effective immunotherapy for specific bladder cancer types.
- Patient stratification and adherence to treatment protocols are paramount for successful BCG therapy.
- BCG offers significant benefits in preventing recurrence and treating existing bladder tumors.